Analytical Data
-
Gene name
LILRA5/CD85f
- Application
-
Alternative Names
CD85 antigen-like family member FImmunoglobulin-like transcript 11 ;ILT-11Leukocyte immunoglobulin-like receptor 9 ;LIR-9; CD85f
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A6NI73
-
Expression Region
42-268aa
-
Molecular Weight
29.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRA5, also known as CD85f, is a member of the leukocyte immunoglobulin-like receptor (LILR) family, which is important for regulating immune responses. This receptor is predominantly expressed on immune cells such as monocytes, dendritic cells, and macrophages, and plays a crucial role in recognizing various ligands, including major histocompatibility complex (MHC) molecules and other immune regulatory proteins. Due to its inhibitory functions, LILRA5/CD85f is thought to be involved in modulating inflammation and preventing excessive immune activation, making it a significant target for understanding autoimmune diseases and other inflammatory conditions.
Recent studies have focused on the recombinant expression of LILRA5/CD85f to investigate its structural properties, ligand interactions, and functional roles in immune regulation. By producing this recombinant protein, researchers aim to elucidate the signaling pathways activated by LILRA5/CD85f and its potential implications in therapeutic strategies for diseases characterized by dysregulated immune responses. Understanding this receptor’s biological mechanisms may pave the way for novel immunotherapies, highlighting the necessity of further exploring the complexities of immune checkpoints and receptor-ligand interactions in the context of disease.
